NEW YORK – Bolt Biotherapeutics said on Wednesday that it closed a $93.5 million Series C financing round led by Sofinnova Investments.
New investors, including RA Capital Management, Surveyor Capital, Rock Springs Capital, Samsara BioCapital, and Pfizer Ventures, participated in the funding round alongside existing investors Novo Holdings, Vivo Capital, Pivotal bioVenture Partners, and others.